DNASTAR and the University of Iowa Sign Lasergene Site License Agreement
News Jan 06, 2010
DNASTAR has announced that the representatives of The University of Iowa in Iowa City, Iowa, have signed a broad site license agreement for the use of Lasergene® sequence analysis software developed by DNASTAR.
Under the terms of the site license, all researchers on the University of Iowa campus will have unlimited access and use of the software for their sequence analysis projects. The license is for a four year period.
The site license includes the latest version of Lasergene, v8.1, which provides users with tools capable of being used in the analysis of Next Generation Sequence data, gene discovery and analysis, automated virtual cloning (including MultiSite Gateway cloning), simultaneous examination of SNP’s from multiple samples, and numerous other features. Upgrades of Lasergene that are released during the contract period are also included.
Bob Steinhauser, DNASTAR’s Director of Marketing stated, “The University of Iowa and DNASTAR have been working together for many years. The site license brings together many different research groups within the University and provides uniformity and standardization of the sequencing software at the University. Site licenses that provide a large number of researchers at a facility access to the use of software are popular at research facilities worldwide because they permit researchers to collaborate much easier. We are extremely pleased that as the activities at the University have grown, DNASTAR has been able to grow with them.”
Lasergene provides users with tools to perform a wide range of DNA assembly, visualization and analysis operations on data generated by the conventional Sanger sequencing method as well as Next Generation platforms.
Google has signed an agreement to join CERN's openlab program. openlab is a public-private partnership with companies and other research organizations to develop information and communication technology (ICT) solutions. Google wants to explore possibilities for joint research and development projects in cloud computing, machine learning, and quantum computing.
With machine learning systems now being used to determine everything from stock prices to medical diagnoses, it's never been more important to look at how they arrive at decisions. A new approach out of MIT demonstrates that the main culprit is not just the algorithms themselves, but how the data itself is collected.